Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Junio 2024 - 11:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2024
Commission File Number: 001-41089
Advanced Health Intelligence Ltd
(Translation of registrant’s name into English)
71-73 South Perth Esplanade, Unit 5
South Perth, WA 6151
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Attached as Exhibit 99.1 to this Report on Form 6-K is a copy of the press
release of Advanced Health Intelligence Ltd, dated June 20, 2024: “ASX provides conditional steps to reinstatement to trading”
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
ADVANCED HEALTH INTELLIGENCE LTD |
|
|
|
Date: June 20, 2024 |
By: |
/s/ Scott Montgomery |
|
|
Name: |
Scott Montgomery |
|
|
Title: |
Chief Executive Officer |
Exhibit 99.1
ASX/NASDAQ Announcement
20 June 2024
|
|
ASX provides conditional steps to reinstatement
to trading
Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI)
(‘AHI’ or ‘the Company’) is pleased to update shareholders that it has received guidelines from
the Australian Securities Exchange (ASX) stating that the Company's securities will be reinstated to trading on the ASX, subject to the
satisfaction of certain conditions precedent.
The conditions precedent required to be satisfied
by the Company before its securities are reinstated to official quotation on the ASX are:
| · | The Company securing AUD$4 million in cleared
funds in the Company’s Bank account, to the satisfaction of the ASX; and |
| · | AHI will confirm the above in an ASX announcement
and release any required ASX forms (including Appendix 3Bs for any proposed security issues). |
The conditional reinstatement of the Company’s
securities to trading on the ASX, is subject to the following caveats:
| · | Upon satisfaction of the previous two bullet
points, ASX intends to reinstate AHI’s securities to official quotation; and |
| · | The ASX has the discretion not to reinstate AHI’s
securities to official quotation should the Company fail to comply with the Listing Rules, the spirit of the Listing Rules, or if other
information comes to light. |
AHI is working to satisfy these conditions
precedent as quickly as possible and will provide shareholders with a further update regarding developments as the Company works towards
reinstatement of its securities to official quotation on the ASX.
The Chairman and CEO of Advanced Health
Intelligence Ltd have approved this announcement.
For more information, contact:
Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech |
Simon Durack JP
Chief Financial Officer
& Company Secretary
Advanced Health Intelligence Ltd
E: admin@ahi.tech |
| Advanced Health Intelligence Ltd. ACN 602 111 115 Postal Address: PO Box 190, South Perth WA 6951 Email: investors@ahi.tech | 1 |
ASX/NASDAQ Announcement 20 June 2024 | |
About Advanced Health Intelligence Ltd
Advanced Health Intelligence
Ltd (AHI) is a pioneering health-tech company that has developed and integrated cutting-edge solutions to revolutionise healthcare globally
and ensure equal access to health assessment for all. Since 2014, AHI has been harnessing the power of smartphone technology to provide
scalable health assessment, risk stratification, and digital triage capabilities to a wide range of healthcare stakeholders worldwide,
including providers, telehealth, insurers, employers, and government agencies.
AHI's proprietary
technology and processes have led to creating a patented biometric health assessment that leverages multiple sensor sets accessible via
smartphone. This comprehensive health evaluation encompasses body dimension and composition assessment, blood biomarker estimation, vital
signs, cardiovascular disease risk estimates, and the detection and management of Atrial Fibrillation. AHI's technology also enables on-device
dermatological skin identification across an impressive 588 skin conditions, including Melanoma.
This groundbreaking
technology offers unparalleled accessibility and convenience, unlocking new possibilities for monitoring health at scale for global populations.
By providing biometrically derived triage solutions accessible on and via a smartphone, AHI empowers its partners to identify risks and
triage consumers into appropriate care pathways for proactive health management at a population scale.
AHI's team of world-class
experts in machine learning, AI, computer vision, and medically trained data scientists drives innovation and improves healthcare outcomes
for individuals worldwide. With a strong commitment to equitability and accessibility, AHI is transforming healthcare globally, one smartphone
at a time.
For more information, please visit: www.ahi.tech
| Advanced Health Intelligence Ltd. ACN 602 111 115 Postal Address: PO Box 190, South Perth WA 6951 Email: investors@ahi.tech | 2 |
Advanced Health Intellig... (CE) (USOTC:MYZQF)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Advanced Health Intellig... (CE) (USOTC:MYZQF)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024